help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mystakidou, K.
Right arrow Articles by Papadimitriou, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mystakidou, K.
Right arrow Articles by Papadimitriou, J.
The Oncologist, Vol. 2, No. 5, 319–323, October 1997
© 1997 AlphaMed Press

Tropisetron versus Metoclopramide in the Control of Emesis in Far-Advanced Cancer

K. Mystakidou, S. Befon, J. Trifyllis, C. Liossi, J. Papadimitriou

Cancer Pain Relief and Palliative Care Unit, University of Athens, Areteion Hospital, Athens, Greece

Correspondence: Kyriaki Mystakidou, M.D., Ph.D., Cancer Pain Relief and Palliative Care Unit, University of Athens, Areteion Hospital, Vas. Sofias 76, 11528 Athens, Greece. Telephone: 30-1-94-334330; Fax: 30-1-7286248.

The present study was conducted to assess the optimum treatment for nausea and vomiting in patients with far advanced cancer. More specifically, we studied patients with cancers that were too far advanced to benefit from chemotherapy or radiotherapy and whose nausea and vomiting were not due to drug intake, cranial, electrolytic, or metabolic causes. One hundred twenty patients who were under antiemetic medication with metoclopramide (MET) and suddenly presented with uncontrolled nausea and vomiting were randomized to three different therapeutic regimens: MET plus dexamethasone (DEX), MET plus tropisetron (TRO), and MET plus TRO plus DEX. Patient diary cards were used to assess nausea and vomiting. By the end of day 15, total control of vomiting was achieved in 24% of MET plus DEX patients, in 84% of MET plus TRO patients, and in 92% of MET plus TRO plus DEX patients. Total control of nausea was achieved in 18% of MET plus DEX patients, in 74% of MET plus TRO patients, and in 87% of MET plus TRO plus DEX patients. All antiemetic treatments were similarly well tolerated. TRO in combination with either MET or MET and DEX produced the best control of both nausea and vomiting.

Key Words. Far advanced cancer • Emesis • Nausea • Vomiting • Tropisetron • Metoclopramide







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 1997 by AlphaMed Press.